RESUMO
The interplay between hepatitis B (HBV) and delta (HDV) viruses is complex and not always characterized during chronic HDV infection. We assessed the clinical usefulness of new quantitative assays for HBV and HDV serum markers in a retrospective cross-sectional study. Sera obtained from 122 HDV genotype 1 and HBV genotype D coinfected, anti-HIV-negative patients (71 males; median age 49.8 [21.7-66.9] years), recruited consecutively in two geographical areas (Italy 69 patients, Romania 53 patients) with different HBV and HDV epidemiology, were tested for HBsAg, HBV-DNA, HBcrAg, total anti-HBc, HDV-RNA, IgM and total anti-HDV using quantitative assays. Cirrhosis, which showed comparable prevalence in the two cohorts, was diagnosed in 97 of 122 (79.5%) patients. At multivariate analysis, cirrhosis was associated with lower total anti-HBc/IgM anti-HDV ratio (OR 0.990, 95% CI 0.981-0.999, P = .038), whereas disease activity was associated with higher total anti-HDV (OR 10.105, 95% CI 1.671-61.107, P = .012) and HDV-RNA levels (OR 2.366, 95% CI 1.456-3.844, P = .001). HDV-RNA serum levels showed a positive correlation with HBV-DNA (ρ = 0.276, P = .005), HBsAg (ρ = 0.404, P < .001) and HBcrAg (ρ = 0.332, P < .001). The combined quantitative profiling of HBV and HDV serum markers identifies specific patterns associated with activity and stage of chronic hepatitis D (CHD). HDV pathogenicity depends on the underlying active HBV infection in spite of the inhibition of its replication. HDV-RNA, IgM anti-HDV, total anti-HDV, total anti-HBc, HBsAg and HBcrAg serum levels qualify for prospective studies to predict progressive CHD and identify candidates to antiviral therapy.
Assuntos
Biomarcadores/sangue , Coinfecção/patologia , Hepatite B Crônica/complicações , Hepatite B Crônica/patologia , Hepatite D Crônica/patologia , Adulto , Idoso , Estudos Transversais , DNA Viral/sangue , Feminino , Genótipo , Anticorpos Anti-Hepatite/sangue , Antígenos do Núcleo do Vírus da Hepatite B/sangue , Antígenos de Superfície da Hepatite B/sangue , Humanos , Imunoglobulina M/sangue , Itália , Masculino , Pessoa de Meia-Idade , RNA Viral/sangue , Estudos Retrospectivos , Romênia , Adulto JovemRESUMO
BACKGROUND: Percutaneous coronary intervention (PCI) on severely calcified coronary lesions is challenging. Coronary calcified nodule (CN) refers to an eccentric and protruding coronary calcification associated with plaque vulnerability and adverse clinical events. This study aims to conduct an extensive review of CNs, focusing on its prognostic impact in comparison with nonnodular coronary calcification (N-CN). METHOD: A systematic literature review on PubMed, MEDLINE, and EMBASE databases was conducted for relevant articles. Observational studies or randomized controlled trials comparing CNs and N-CNs were included. RESULTS: Five studies comparing CNs and N-CNs were pertinent for inclusion. The total number of individuals across these studies was 1456. There were no significant differences in the baseline demographic, clinical, and angiographic data between the CN and N-CN groups. Intracoronary imaging was always utilized. At follow-up, CNs were associated with significantly increased, target vessel revascularization [odds ratio (OR) 2.16; 95% confidence interval (CI): 1.39-3.36, P-value < 0.01, I2â=â0%] and stent thrombosis (OR 9.29; 95% CI: 1.67-51.79, P-valueâ=â0.01, I2â=â0%) compared with N-CN. A trend for greater cardiac death was also assessed in the CN group (OR 1.75; 95% CI: 0.98-3.13, P-valueâ=â0.06, I2â=â0%). CONCLUSION: CN has a significantly negative impact on outcomes when compared with N-CN.
Assuntos
Doença da Artéria Coronariana , Intervenção Coronária Percutânea , Calcificação Vascular , Humanos , Doença da Artéria Coronariana/terapia , Doença da Artéria Coronariana/diagnóstico por imagem , Calcificação Vascular/diagnóstico por imagem , Calcificação Vascular/terapia , Intervenção Coronária Percutânea/efeitos adversos , Fatores de Risco , Angiografia Coronária , Resultado do Tratamento , Masculino , Feminino , Pessoa de Meia-Idade , Medição de Risco , IdosoRESUMO
Mycoplasmas have been isolated from birds of prey during clinical examinations, but their significance to the health of raptors is unclear. We report the isolation and characterization of four mycoplasmas found in the upper respiratory tract of four sick Eurasian Griffon (Gyps fulvus) that were housed in a Sicilian rehabilitation center at Ficuzza, near Palermo in Sicily, before reintroduction into the wild. These included Mycoplasma gallinarum, an unidentified mycoplasma highly similar to Mycoplasma glycophilum, and two unidentified mycoplasmas with similarities to Mycoplasma falconis and Mycoplasma gateae.
Assuntos
Doenças das Aves/microbiologia , Infecções por Mycoplasma/veterinária , Mycoplasma/isolamento & purificação , Aves Predatórias/microbiologia , Animais , Animais Selvagens/microbiologia , Sequência de Bases , Doenças das Aves/epidemiologia , DNA Bacteriano/análise , DNA Ribossômico/análise , Eletroforese em Gel de Ágar/métodos , Eletroforese em Gel de Ágar/veterinária , Dados de Sequência Molecular , Mycoplasma/classificação , Infecções por Mycoplasma/epidemiologia , Infecções por Mycoplasma/microbiologia , Filogenia , Reação em Cadeia da Polimerase/métodos , Reação em Cadeia da Polimerase/veterinária , Sicília/epidemiologia , Traqueia/microbiologiaRESUMO
Hepatitis C virus (HCV) infection is associated with a wide spectrum of liver disease ranging from asymptomatic carriage to severe forms of chronic hepatitis. HCV is not invariably pathogenic and genetic heterogeneity of HCV could be a major cause of such a variability. In clinical practice this means that presence and replication of the virus do not invariably imply a virus-induced liver damage. IgM antibodies that are the best diagnostic tools for the other forms of viral hepatitis are not sensitive and specific enough for hepatitis C, therefore we have to look for alternatives. Detection of anti-HCV does not help to distinguish past from present infections and only anti-HCV seroconversion in previously negative patients can indicate a recent HCV infection. However, the significant association between serum anti-C100-3 and HCV-RNA suggests that anti-HCV can be considered an indirect marker of HCV infectivity. In anti-HCV-negative infections and early acute hepatitis cases HCV-RNA detection will represent a valid diagnostic alternative. In patients undergoing antiviral therapy monitoring anti-HCV by immunoblotting assays and HCV-RNA by quantitative assays represent a valid tool to predict response that invariably has occurred in patients who had undetectable serum HCV-RNA and/or decreasing anti-HCV titres. Assays that detect multiple anti-HCV antibodies all together appear unsuitable for monitoring because they miss the disappearance of single antibodies. Anti-C22 appears the most frequent and earliest to be detected and usually it has the highest titre. Anti-C100 titres decrease earlier than anti-C33 and anti-C22 in patients with chronic HCV hepatitis who respond to antiviral therapy. The natural course of HCV infection appears to be characterized by three consecutive phases: disease, asymptomatic carrier and recovery. If transition from the first to the last occurs very slowly or the disease phase persists for years it may warrant in susceptible hosts severe forms of liver disease.
Assuntos
Hepatite C/complicações , Hepatopatias/etiologia , Hepacivirus/genética , Hepacivirus/imunologia , Anticorpos Anti-Hepatite/sangue , Hepatite C/imunologia , Hepatite C/transmissão , Anticorpos Anti-Hepatite C , Humanos , RNA Viral/análiseRESUMO
The development of anti-interferon (anti-IFN) antibodies in the serum of patients undergoing antiviral therapy has been postulated as one possible cause of interpatient variability in response to therapy. We analyzed the relationship between the appearance of anti-IFN antibodies and the loss of response to interferon-alpha (IFN-alpha), as characterized by a breakthrough of serum aminotransferase after a period of complete biochemical remission. The analysis involved clinical trials where neutralizing anti-IFN antibodies were detected by standardized and comparable methods. The results show that a time relationship between breakthrough and anti-IFN antibodies is observed in only a few cases and is independent of the type of IFN-alpha preparation used. Thus, causes of IFN resistance other than anti-IFN antibodies must also be implicated in most breakthrough cases. Another potential is the selection of drug-resistant viral strains. Current ration behavior following the appearance of breakthrough (from whatever cause) in clinical practice advocates changing treatment to a different type of IFN-alpha. The detection of anti-IFN enzyme-linked immunosorbent assay (ELISA) antibodies or IFN neutralizing antibodies does not appear to provide any additional information for decision making.
Assuntos
Autoanticorpos/análise , Hepatite C/tratamento farmacológico , Interferon Tipo I/uso terapêutico , Alanina Transaminase/sangue , Reações Antígeno-Anticorpo , Doença Crônica , Esquema de Medicação , Ensaio de Imunoadsorção Enzimática , Humanos , Interferon Tipo I/imunologia , Proteínas RecombinantesRESUMO
We describe the case of a HBsAg+, HBeAg+ carrier, treated with lamivudine, who experienced exacerbation of hepatitis after BMT from an anti-HBs+, anti-HBc+, anti-HBe+ donor. The serological profile of the donor and the timing of exacerbation suggested that the adoptive immunity transfer played a major pathogenetic role. Antilymphocyte globulin administration resulted in resolution of hepatitis and seroconversion to anti-HBs+. Therapy aimed at blocking the effector arm of liver damage could represent a novel approach to avoid the risk of progression to fulminant hepatitis without hampering the chances of recovery from hepatitis B.
Assuntos
Transferência Adotiva , Soro Antilinfocitário/uso terapêutico , Transplante de Medula Óssea/efeitos adversos , Antígenos de Superfície da Hepatite B/genética , Hepatite B/patologia , Imunoterapia Adotiva/métodos , Animais , Antivirais/uso terapêutico , Criança , Progressão da Doença , Feminino , Vírus da Hepatite B/metabolismo , Heterozigoto , Teste de Histocompatibilidade , Cavalos , Humanos , Lamivudina/uso terapêutico , Fígado/patologia , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Fatores de Tempo , Doadores de TecidosRESUMO
Early diagnosis of hepatitis C infection and early identification of virologic response to antiviral therapy represent major hallmarks of the quality of a case. They contribute to reducing the risk of hepatitis C infection from blood product and improve disease management in patients treated with antivirals. Some of the current issues and perspectives involved in detection and quantification of viral load during the incubation phase of infection and monitoring the early phase of antiviral therapy are discussed.
Assuntos
Antivirais/uso terapêutico , Hepacivirus/genética , Hepatite C/diagnóstico , Hepatite C/genética , Farmacogenética , Humanos , Técnicas de Amplificação de Ácido Nucleico/métodos , Fatores de RiscoRESUMO
AIMS: To evaluate whether high numbers of silver staining nucleolar organiser regions (AgNORs) in hepatocytes are associated with increased risk of hepatocellular carcinoma in chronic liver disease. METHODS: The quantitative distribution of AgNORs was studied in the liver biopsy specimens of 33 patients with chronic liver disease, 11 of whom developed hepatocellular carcinoma. The interval between liver biopsy and diagnosis of hepatocellular carcinoma was 26 months (range one to 61 months); the mean follow up of patients without hepatocellular carcinoma was 45 months (range 24-59 months). Quantitative evaluation of AgNORs was carried out on silver stained routine sections by morphometric analysis, using a computer assisted image analysis system. RESULTS: High interphase AgNOR values (> 3 microns2) were found in hepatocytes of nine out of the 11 (82%) patients in whom neoplastic transformation occurred. Of the remaining 22 patients, only seven (31%) had AgNOR values higher than > 3 microns2 (chi 2 4.83; p = 0.036). CONCLUSIONS: These results indicate that high numbers of interphase AgNORs are associated with increased risk of hepatocellular carcinoma in patients with chronic liver disease.
Assuntos
Carcinoma Hepatocelular/patologia , Hepatite Crônica/patologia , Neoplasias Hepáticas/patologia , Fígado/patologia , Região Organizadora do Nucléolo/patologia , Adulto , Idoso , Transformação Celular Neoplásica/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Fatores de TempoRESUMO
BACKGROUND AND AIMS: Complete [biochemical and virological) primary response remains the first goal of any antiviral therapy and its early assessment could be particularly useful in the management of the high viral load, genotype 1b infected patients, who have the worst chance of response. We evaluated whether tailoring interferon dose according to pre-treatment viral load and early monitoring of quantitative HCV-RNA could either improve or predict the results of recombinant alpha-2a interferon treatment in these patients. PATIENTS: Fifty-three consecutive genotype 1b HCV-infected patients, stratified in two groups by viral load (cut off 6 MEq/ml), received randomly 6 or 9 MU of recombinant alpha-2a interferon thrice weekly for 6 months, followed by 6 MU for another 6 months. METHODS: HCV-RNA was measured [b-DNA] assay) two months apart prior to therapy, at baseline, after 2 weeks of therapy and monthly thereafter. RESULTS: In the high viraemic group, complete primary response was observed in 80% of patients treated with high dose recombinant alpha 2a interferon and only in 14.3% of low dose treated patients [p<0.03]. In low viraemic patients, complete primary response was 53. 8% in low dose patients and 80% (8 out of 10) in the high dose group. Sustained response was 60% in high viraemic patients treated with high dose and absent in those treated with low dose [p<0.05]. One log viral load decrease at 2 or 4 weeks showed 0.87 and 0.80 positive predictive values, 0.95 and 1.0 negative predictive values with 96% and 100% sensitivities and 83% and 70% specificities. CONCLUSIONS: 6 MU recombinant alpha-2a interferon thrice weekly schedules were completely ineffective in the large majority (85.7%) of patients with viral load above 6 million HCV-RNA copies/ml and the treatment failure could be predicted by lack of one log viral load decrease after 2-4 weeks of treatment.
Assuntos
Antivirais/administração & dosagem , Hepacivirus , Anticorpos Anti-Hepatite C/análise , Hepatite C Crônica/tratamento farmacológico , Interferon-alfa/administração & dosagem , RNA Viral/análise , Carga Viral/métodos , Adulto , Relação Dose-Resposta a Droga , Feminino , Hepacivirus/genética , Hepacivirus/imunologia , Hepatite C Crônica/virologia , Humanos , Interferon alfa-2 , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Prognóstico , Proteínas Recombinantes , Viremia/tratamento farmacológico , Viremia/virologiaRESUMO
Hepatic carcinogenesis is a complex process that involves profound alterations of the hepatocyte genome (1,2) and has been graded in three stages: induction, promotion, and progression in the animal models (3-5). In recent years, the use of molecular biology techniques have improved significantly the understanding of the mechanisms (alteration of gene and gene expression) that occur during the different steps of carcinogenesis.
RESUMO
Bronchial carcinoid is the most frequent cause of Cushing's syndrome due to ectopic ACTH production. The authors report a case of bronchial carcinoid which diagnosis was difficult because of the presence of pulmonary mycosis, that determined a hypercorticosuprarenalism. Medical treatment with octreotide, ketoconazolo and mitotane was useless, and bilateral suprarenalectomy was performed. A scintigraphy with raced somatostatin revealed a left lung area capting radiation. A CT scan of the thorax revealed a lesion of the lingula and the patient underwent an atypical lung resection with complete solution of the symptom. The problems of diagnosis and treatment of neuroendocrine tumors of the lung are discussed and the importance of SSA in the diagnostic procedure is pointed out.
Assuntos
Neoplasias Brônquicas/complicações , Tumor Carcinoide/complicações , Síndrome de Cushing/etiologia , Síndrome de ACTH Ectópico , Hormônio Adrenocorticotrópico/metabolismo , Adulto , Neoplasias Brônquicas/diagnóstico , Neoplasias Brônquicas/metabolismo , Neoplasias Brônquicas/terapia , Tumor Carcinoide/diagnóstico , Tumor Carcinoide/metabolismo , Tumor Carcinoide/terapia , Síndrome de Cushing/diagnóstico , Hormônios Ectópicos/metabolismo , Humanos , Hidrocortisona/metabolismo , Pneumopatias Fúngicas/complicações , Pneumopatias Fúngicas/diagnóstico , MasculinoAssuntos
Hepatite B/diagnóstico , Hepatite C/diagnóstico , Transplante de Fígado/fisiologia , Complicações Pós-Operatórias/virologia , DNA Viral/isolamento & purificação , Seguimentos , Hepatite B/prevenção & controle , Hepatite C/prevenção & controle , Humanos , Monitorização Fisiológica/métodos , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/prevenção & controle , RNA Viral/isolamento & purificação , Recidiva , Sensibilidade e Especificidade , Fatores de TempoAssuntos
Rejeição de Enxerto/diagnóstico , Anticorpos Anti-Hepatite C/sangue , Hepatite C/diagnóstico , Imunoglobulina M/sangue , Transplante de Fígado , Doença Aguda , Adulto , Biópsia por Agulha , Diagnóstico Diferencial , Feminino , Seguimentos , Humanos , Transplante de Fígado/patologia , Masculino , Pessoa de Meia-Idade , RNA Viral/sangue , Recidiva , Sensibilidade e Especificidade , Fatores de TempoAssuntos
Antivirais/uso terapêutico , Hepatite B/prevenção & controle , Hepatite B/cirurgia , Transplante de Fígado/efeitos adversos , Seguimentos , Sobrevivência de Enxerto , Hepatite B/epidemiologia , Antígenos de Superfície da Hepatite B/sangue , Humanos , Transplante de Fígado/mortalidade , Complicações Pós-Operatórias/prevenção & controle , Complicações Pós-Operatórias/virologia , Recidiva , Análise de Sobrevida , Fatores de TempoAssuntos
Hepatite Viral Humana/diagnóstico , Adulto , Biomarcadores , Diagnóstico Diferencial , Feminino , Hepacivirus/genética , Hepacivirus/imunologia , Anticorpos Anti-Hepatite B/análise , Antígenos de Superfície da Hepatite B/análise , Vírus da Hepatite B/genética , Vírus da Hepatite B/imunologia , Anticorpos Anti-Hepatite C/análise , Vírus Delta da Hepatite/genética , Vírus Delta da Hepatite/imunologia , Humanos , Imunoglobulina M/análise , Recém-Nascido , Masculino , RNA Viral/análiseRESUMO
A novel biomathematical model that analyzes the combined alanine transaminase (ALT) and viral-load kinetics during the first month of pegylated interferon (Peg-IFN) plus ribavirin (RBV) therapy was successfully applied in 90 of 97 (93%) chronic hepatitis C patients in order to compute the number of infected cells at the end of therapy (I(eot)). The I(eot) indices were lower in sustained virological responders than in relapsers (RELs) and nonresponders (NRs) (median values: 31 vs. 2,190 vs. 1,090,000; P < 0.001), and were independently associated with treatment outcomes (P = 0.003). A threshold of 250 I(eot) was shown to identify sustained virological response (SVR) with high positive predictive value (93%) and good diagnostic accuracy (81%). The time taken to attain 250 I(eot) ranged from 3 to 11 months in patients with hepatitis C virus (HCV) genotypes 2 or 3 and from 3 to 18 months in those with HCV genotypes 1 or 4. Overall, the duration of therapy would have been 49 months less than that suggested by the most recent algorithms based on a rapid virological response (RVR) at week 4.